Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Psoriasis;Arthritis, Psoriatic, Date of authorisation: 26/04/2019, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Psoriasis;Arthritis, Psoriatic, Date of authorisation: 26/04/2019, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Psoriasis;Arthritis, Psoriatic, Date of authorisation: 26/04/2019, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Psoriasis;Arthritis, Psoriatic, Date of authorisation: 26/04/2019, Revision: 14, Status: Authorised

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Psoriasis;Arthritis, Psoriatic, Date of authorisation: 26/04/2019, Revision: 14, Status: Authorised

Wil je het laatste nieuws in jouw mailbox ontvangen?
Meld je dan aan voor de nieuwsbrief.